Research Progress in Treatment of Chronic Lymphocytic Leukemia --Review.
10.19746/j.cnki.issn.1009-2137.2023.06.049
- Author:
Ran ZHANG
1
;
Ran XIN
2
;
Li-Ping DOU
3
;
Yu JING
4
Author Information
1. Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
2. Nankai University School of Medicine, Tianjin 300071, China.
3. Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China .E-mail: lipingruirui@163.com.
4. Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.E-mail：jingyu301@126.com.
- Publication Type:Journal Article
- Keywords:
BCL-2 inhibitor;
BTK inhibitor;
chimeric antigen receptor-modified T cells;
chronic lymphocytic leukemia
- MeSH:
Humans;
Hematopoietic Stem Cell Transplantation;
Immunotherapy;
Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy*;
Signal Transduction
- From:
Journal of Experimental Hematology
2023;31(6):1910-1915
- CountryChina
- Language:Chinese
-
Abstract:
Chronic lymphocytic leukemia (CLL) is a low-grade lymphoproliferative tumor that occurs frequently in middle-aged and elderly people. Early and precise intervention can effectively improve the clinical prognosis of CLL patients. In the past, chemotherapy was the main treatment plan. With the development of molecular biology and the continuous advent of immune targeting drugs, targeted drugs targeting B cell receptor signaling pathway have shown high clinical application value in the diagnosis and treatment path of CLL. Cellular immunotherapies such as CAR-T also offer hope for patients with relapsed and refractory CLL. Allogeneic hematopoietic stem cell transplantation and multi-drug combination have also shown remarkable results in clinical practice. The purpose of this article is to review the latest research progress in the treatment of CLL.
